Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome

Journal of International Medical Research

Volumn 34, Issue 5, 2006, Pages 545-555

  Derosa, G ^a   D'Angelo, A ^a   Ragonesi, P D ^b   Ciccarelli, L ^a   Piccinni, M N ^a   Pricolo, F ^a   Salvadeo, S ^a   Montagna, L ^a   Gravika, A ^a   Ferrari, I ^a   Galli, S ^a   Paniga, S ^a   Cicero, A F G ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Fibrinolysis; Metabolic syndrome; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXERCISE; FEMALE; FIBRINOLYSIS; FLATULENCE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 33751023986     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400513     Document Type: Article

References (39)

1. Biondi-Zoccai GG Abbate A, Liuzzo G, Biasucci LM: Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003; 41: 1071-1077.
2. Abbott RD, Curb JD, Rodriguez BL, Masaki KH, Popper JS, Ross GW, et al: Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. J Clin Epidemiol 2003; 56: 479-486.
3. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR: Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
4. Theuma P, Fonseca VA: Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 2003; 3: 248-254.
5. Liu S, Willett WC: Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002; 4: 454-461.
6. Reusch JE: Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002; 90: 19G-26G.
7. Tsikouris IP, Suarez JA, Meyerrose GE: Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002; 42: 1187-1199.
8. Ghosh K: Thrombohaemorrhagic balance in diabetes mellitus. J Indian Med Assoc 2002; 100: 428, 430, 432-433.
9. Calverley DC, Hacker MR, Lodo KA, Brass E, Buchanan TA, Tsoo-Wei DD, et al: Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003; 121: 139-142.
10. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Faster V, et al: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
11. Grant PJ: Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44-6S52.
12. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, et al: A comparison of the effects of pioglitozone and rosiglitozone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diab Res Clin Pract 2005; 69: 5-13.
13. American Diabetes Association: Screening for diabetes (Position Statement). Diabetes Care 2001; 24 (Suppl 1): S21-S24.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. Guidelines Subcommittee: 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
16. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of the WHO Consultation on Obesity. Geneva: WHO, 1997.
17. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 (Suppl 1): S44-S47.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Bunn HF, Gobboy KH, Gallop PM: The glycosylation of haemoglobin: relevance to diabetes mellitus. Science 1978; 200: 21-27.
20. European Diabetes Policy Group 1999: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
21. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
22. Juhan-Vague I, Collen D: On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
23. Clauss A: Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens (in German). Acta Haematol 1959; 17: 237-246.
24. Narayanan S: Preanalytical aspects of coagulation testing. Haematologica 1995; 80 (Suppl): 1-6.
25. Bergmeyer HU, Horder M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section. Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1) J Clin Chem Biochem 1986; 24: 497.
26. Bergmeyer HU, Harder M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Biochem 1986; 24: 481.
27. Winer BJ (ed): Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill, 1971.
28. American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl 1): S1-S147.
29. Charpentier G, Fleury F, Kabir M, Vaur L, Holimi S: Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-834.
30. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (Suppl 6a): 15S-22S.
31. Vague P: Is metformin more than an oral hypoglycoemic agent? Diabetes Metab 2003; 29: 6SS-6S7.
32. Johnson JA, Simpson SH, Majumdar SR, Toth EL: Decreased mortality associated with the use of metformin compared with sulphonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
33. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
34. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
35. Despres JP: Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 2003; 29: 6S53-6S61.
36. Ovalle F, Fernando OB: Thiazolidinediones: a review of their benefits and risks. South Med J 2002; 95: 1188-1194.
37. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, et al: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396.
38. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
39. Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, Kumor S: Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 2003; 5: 302-310.